JP2021521138A - Ｂｃｌ−２阻害剤 - Google Patents

Ｂｃｌ−２阻害剤 Download PDF

Info

Publication number
JP2021521138A
JP2021521138A JP2020555218A JP2020555218A JP2021521138A JP 2021521138 A JP2021521138 A JP 2021521138A JP 2020555218 A JP2020555218 A JP 2020555218A JP 2020555218 A JP2020555218 A JP 2020555218A JP 2021521138 A JP2021521138 A JP 2021521138A
Authority
JP
Japan
Prior art keywords
ring
heterocyclyl
alkyl
compound according
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020555218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521138A5 (enExample
Inventor
グオ、ユンハン
シュエ、ハイ
ワン、ジウェイ
ソン、ハンジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
BeOne Medicines Ltd
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines Ltd, Beigene Ltd filed Critical BeOne Medicines Ltd
Publication of JP2021521138A publication Critical patent/JP2021521138A/ja
Publication of JP2021521138A5 publication Critical patent/JP2021521138A5/ja
Priority to JP2024094048A priority Critical patent/JP7540113B1/ja
Priority to JP2024135320A priority patent/JP7688210B2/ja
Priority to JP2025085498A priority patent/JP2025119001A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
JP2020555218A 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤 Withdrawn JP2021521138A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024094048A JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/085217 2018-04-29
CN2018085217 2018-04-29
CNPCT/CN2018/107134 2018-09-21
CN2018107134 2018-09-21
PCT/CN2019/085001 WO2019210828A1 (en) 2018-04-29 2019-04-29 Bcl-2 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094048A Division JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤

Publications (2)

Publication Number Publication Date
JP2021521138A true JP2021521138A (ja) 2021-08-26
JP2021521138A5 JP2021521138A5 (enExample) 2022-04-22

Family

ID=68386968

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020555218A Withdrawn JP2021521138A (ja) 2018-04-29 2019-04-29 Ｂｃｌ−２阻害剤
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024094048A Active JP7540113B1 (ja) 2018-04-29 2024-06-11 Ｂｃｌ－２阻害剤
JP2024135320A Active JP7688210B2 (ja) 2018-04-29 2024-08-14 Ｂｃｌ－２阻害剤
JP2025085498A Pending JP2025119001A (ja) 2018-04-29 2025-05-22 Ｂｃｌ－２阻害剤

Country Status (22)

Country Link
US (3) US11420968B2 (enExample)
EP (2) EP4545515A1 (enExample)
JP (4) JP2021521138A (enExample)
KR (1) KR102738032B1 (enExample)
CN (3) CN112437772B (enExample)
AU (1) AU2019264475C1 (enExample)
BR (1) BR112020022092A2 (enExample)
CA (1) CA3098348A1 (enExample)
DK (1) DK3788042T3 (enExample)
ES (1) ES3018793T3 (enExample)
FI (1) FI3788042T3 (enExample)
HR (1) HRP20250392T1 (enExample)
HU (1) HUE071493T2 (enExample)
IL (1) IL278366B2 (enExample)
LT (1) LT3788042T (enExample)
MX (2) MX2020011495A (enExample)
PL (1) PL3788042T3 (enExample)
PT (1) PT3788042T (enExample)
SG (1) SG11202009933WA (enExample)
SI (1) SI3788042T1 (enExample)
TW (1) TWI855062B (enExample)
WO (1) WO2019210828A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119916A (ja) * 2018-04-29 2024-09-03 ベイジーン リミテッド Ｂｃｌ－２阻害剤
JP2024540534A (ja) * 2021-12-06 2024-10-31 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
EP3612531B1 (en) 2017-04-18 2022-08-24 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
IL296582A (en) * 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
US20230159527A1 (en) * 2020-05-08 2023-05-25 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
CN114478520B (zh) * 2020-10-28 2025-01-10 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
MX2023011000A (es) * 2021-03-19 2023-09-28 Eil Therapeutics Inc Compuestos que contienen ((3-nitrofenilo)sulfonilo)acetamida como inhibidores bcl-2.
WO2022218311A1 (en) * 2021-04-13 2022-10-20 Appicine Therapeutics (Hk) Limited Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
EP4351542A4 (en) * 2021-06-02 2025-04-09 BeiGene Switzerland GmbH Method for treating B-cell malignancy with BCL-2 inhibitor
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
EP4396180A4 (en) * 2021-08-31 2025-07-09 Beigene Ltd SOLID FORMS OF BCL-2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
US20250122191A1 (en) * 2021-11-20 2025-04-17 Fochon Biosciences, Ltd Compounds as bcl-2 inhibitors
TW202400163A (zh) 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
JP2025525609A (ja) * 2022-07-21 2025-08-05 ベイジーン スイッツァランド ゲーエムベーハー Ｂｃｌ－２阻害剤を使用する多発性骨髄腫の治療方法
AU2023417649A1 (en) * 2022-12-27 2025-08-14 Beone Medicines I Gmbh Intermediates of sonrotoclax and the method of preparing the same
KR20250127311A (ko) * 2022-12-27 2025-08-26 비원 메디슨즈 아이 게엠베하 손로토클락스를 위한 케탈 보호된 중간체 및 이의 제조 방법
IL321700A (en) * 2022-12-27 2025-08-01 Beone Medicines I Gmbh Salts and solid forms of sonrotoclax intermediate
WO2026002056A1 (en) 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof
WO2026019442A1 (en) * 2024-07-14 2026-01-22 Eil Therapeutics, Inc. Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528178A (ja) * 2009-05-26 2012-11-12 アボット・ラボラトリーズ 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2013527202A (ja) * 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
CN106749233A (zh) * 2016-11-24 2017-05-31 中山大学 一类磺酰胺衍生物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AU2005277223C1 (en) 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
MX2007014783A (es) 2005-05-24 2008-02-19 Abbott Lab Activadores de apoptosis.
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
US8501992B2 (en) 2008-06-09 2013-08-06 Bristol-Myers Squibb Company Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2376480T3 (en) 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8759520B2 (en) 2008-12-08 2014-06-24 Boehringer Ingelheim International Gmbh Compounds for treating cancer
CA2747835A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083442A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2772989A1 (en) 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
RU2015141713A (ru) 2010-03-25 2018-12-28 Эббви Инк. Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
IT1403156B1 (it) 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
EP2668180B1 (en) 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
JP2014521595A (ja) 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
US8946445B2 (en) 2011-10-12 2015-02-03 Nanjing Allgen Pharma Co., Ltd. Heterocyclic molecules as apoptosis inducers
WO2013096051A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015308A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
EP3689886A1 (en) 2013-01-16 2020-08-05 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
US10829488B2 (en) 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2018041248A1 (zh) 2016-09-01 2018-03-08 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
EP3612531B1 (en) 2017-04-18 2022-08-24 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
CN111511748B (zh) 2017-08-23 2023-05-02 广州麓鹏制药有限公司 Bcl-2抑制剂
SG11202009933WA (en) * 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528178A (ja) * 2009-05-26 2012-11-12 アボット・ラボラトリーズ 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2013527202A (ja) * 2010-05-26 2013-06-27 アッヴィ・インコーポレイテッド 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
CN106749233A (zh) * 2016-11-24 2017-05-31 中山大学 一类磺酰胺衍生物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRUG AND METABOLISM AND DISPOSITION, vol. 45(3), JPN6023040641, 2017, pages 294 - 305, ISSN: 0005165092 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119916A (ja) * 2018-04-29 2024-09-03 ベイジーン リミテッド Ｂｃｌ－２阻害剤
JP2024540534A (ja) * 2021-12-06 2024-10-31 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用
JP7765790B2 (ja) 2021-12-06 2025-11-07 杭州和正医薬有限公司 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用

Also Published As

Publication number Publication date
CA3098348A1 (en) 2019-11-07
LT3788042T (lt) 2025-03-25
TWI855062B (zh) 2024-09-11
US12077536B2 (en) 2024-09-03
KR102738032B1 (ko) 2024-12-05
PT3788042T (pt) 2025-04-15
JP7540113B1 (ja) 2024-08-26
ES3018793T3 (en) 2025-05-19
US20210269433A1 (en) 2021-09-02
HRP20250392T1 (hr) 2025-05-23
AU2019264475B2 (en) 2024-09-26
AU2019264475C1 (en) 2025-01-30
HUE071493T2 (hu) 2025-09-28
CN112437772B (zh) 2023-11-21
DK3788042T3 (en) 2025-04-07
JP7688210B2 (ja) 2025-06-03
IL278366B2 (en) 2025-09-01
CN117430601A (zh) 2024-01-23
US20240376104A1 (en) 2024-11-14
JP2025119001A (ja) 2025-08-13
MX2023001689A (es) 2023-02-22
CN112437772A (zh) 2021-03-02
EP3788042B1 (en) 2025-02-12
KR20210005677A (ko) 2021-01-14
EP3788042A1 (en) 2021-03-10
BR112020022092A2 (pt) 2021-02-02
WO2019210828A1 (en) 2019-11-07
IL278366B1 (en) 2025-05-01
MX2020011495A (es) 2021-01-15
IL278366A (enExample) 2020-12-31
SG11202009933WA (en) 2020-11-27
EP4545515A1 (en) 2025-04-30
AU2019264475A1 (en) 2020-11-12
TW202043217A (zh) 2020-12-01
US20220402915A1 (en) 2022-12-22
SI3788042T1 (sl) 2025-06-30
EP3788042A4 (en) 2022-01-26
PL3788042T3 (pl) 2025-06-02
US11420968B2 (en) 2022-08-23
FI3788042T3 (fi) 2025-04-07
CN117683029A (zh) 2024-03-12
JP2024161475A (ja) 2024-11-19
JP2024119916A (ja) 2024-09-03

Similar Documents

Publication Publication Date Title
JP7688210B2 (ja) Ｂｃｌ－２阻害剤
AU2017279014B2 (en) Substituted carbonucleoside derivatives useful as anticancer agents
JP2022517222A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN113905787A (zh) Mettl3抑制化合物
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
CN114929689A (zh) Bcl-2抑制剂
JP7839790B2 (ja) Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体
CN105732636A (zh) 杂芳化合物及其在药物中的应用
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CN114302886A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
EA043978B1 (ru) ИНГИБИТОРЫ Bcl-2
HK40038513A (en) Bcl-2 inhibitors
HK40038513B (en) Bcl-2 inhibitors
HK40078656A (en) Bcl-2 inhibitors
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
OA19125A (en) Substituted carbonucleoside derivatives useful as anticancer agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240710